Specify a stock or a cryptocurrency in the search bar to get a summary
Hikma Pharmaceuticals PLC
HIKHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom. Address: 1 New Burlington Place, London, United Kingdom, W1S 2HR
Analytics
WallStreet Target Price
179 326.96 GBXP/E ratio
27.8333Dividend Yield
4.39 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures HIK
Dividend Analytics HIK
Dividend growth over 5 years
77 %Continuous growth
7 yearsPayout Ratio 5 years average
54 %Dividend History HIK
Stock Valuation HIK
Financials HIK
Results | 2019 | Dynamics |